Recombinant human LCAT (rhLCAT), which raises HDL-C and increases cholesterol efflux, was shown to be safe in a phase I study (Shamburek et al., 2016b) and is now in phase II trials for CHD (clinicaltrials.gov, NCT02601560, NCT03578809). The gene discussed is LCAT; the disease is coronary artery disorder.